drugset / Trial / NCT04224701
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults
Phase 1
Completed
48 enrolled
International AIDS Vaccine Initiative
Amsterdam UMC, location VUmc · collabGeorge Washington University · collabGlaxoSmithKline · collabRockefeller University · collab
RandomizedSequentialDouble-blindPrevention
Summary
This is a phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 trimer Vaccine, Adjuvanted, in up to 48 healthy HIV-uninfected adult volunteers.
Timeline
- Start
- 2020-08-01
- Primary completion
- 2023-07-05
- Completion
- 2023-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG505 SOSIP GT1.1 gp140 | Vaccine | 30 ug | Intramuscular |
| Subject | BG505 SOSIP GT1.1 gp140 | Vaccine | 300 ug | Intramuscular |